Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
HyPerMICROBE is a single-centre, controlled, randomised, prospective, superiority clinical trial to compare the efficacy of daily oral care with 3% hydrogen peroxide (Oroxid®) versus standard of care (0.2% chlorhexidine digluconate) on the cumulative incidence of lower respiratory tract microbial colonisation in mechanically ventilated adult critically ill patients.
Rationale: Ventilator-associated pneumonia (VAP) is the most common hospital-acquired infection (HAI) in the intensive care unit (ICU), and its impact is very high in terms of morbidity, length of hospital stay and overall costs. Chlorhexidine for oral care in critically ill has no clear impact on VAP rates and may cause harm. 3% hydrogen peroxide (Oroxid) could be a promising substitute.
Aim: To test effectivity and safety of 3% hydrogen peroxide solution on ventilator-associated complications
Design: Prospective, single center, parallel group randomised controlled trial. Subjects: ICU patients (general ICU)
Treatment in the intervention group: daily oral care with 3% hydrogen peroxide
Control group: Standard-of-care protocolised daily oral care with 0,2% chlorhexidine
Primary outcome: Cumulative incidence of lower respiratory tract microbial colonisation analysed by Kaplan-Maier method, censored in the case of ICU discharge or extubation > 24h.
Secondary and exploratory outcomes: Differences in the relative risk of infection related ventilator-associated complications, antibiotic (ATB) consumption analysis, intraoral complications, reported using the Bedside oral exam (BOE) score, validated and adopted for ICU, length of ICU stay in days (time frame: at 3 months), number of ventilator-free days (time frame: at 28 days); that is, number of days, out of 28 days after admission, that patient has not been supported by mechanical ventilation
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Hydrogen Peroxide | Experimental | Intervention group: daily oral care will be provided according to the local standard, with 3% hydrogen peroxide, oral assessment and teeth brushing will be completed twice daily (morning and evening). |
|
| Chlorhexidine | Active Comparator | Control group: daily oral care will be provided according to the local standard, with 0,2% chlorhexidine, oral assessment and teeth brushing will be completed twice daily (morning and evening). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oroxid® | Drug | All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local "ventilator bundle "; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using Oroxid® mouthwash. |
| Measure | Description | Time Frame |
|---|---|---|
| Cumulative incidence of lower respiratory tract microbial colonisation analysed by Kaplan-Maier method, censored in the case of ICU discharge or extubation > 24h. | To detect microorganisms in the lower respiratory tract, tracheal aspirate will be directly cultured for detecting Gram-positive, Gram-negative, and anaerobic bacteria and fungi. Standard microbial surveillance (tracheal aspirate) will be performed on admission, twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. | 18 months |
| Measure | Description | Time Frame |
|---|---|---|
| Differences in the relative risk of infection related ventilator associated complications (IVAC) | According to the Centers for Disease Control and Prevention (CDC) criteria, the IVAC diagnosis will be established based on:
|
| Measure | Description | Time Frame |
|---|---|---|
| Composition of the oral and lower airway microbiome between groups measured by the bacterial 16S rRNA sequencing | Microbial DNA will be sequentially (on admission, day 3, 7 and 14) sampled and isolated from prespecified sites in oral cavity, hypopharynx and lower respiratory tract. Microbial DNA will be analyzed by 16S rRNA amplicon sequencing and quantified by multiplex qPCR method. Paired comparison of bacteriomes between intervention group and control group will be performed to identify potentially risky host bacteriome profiles. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Kateřina Rambousková, MD | Contact | +420 721 185 134 | kacakoubkova@seznam.cz | |
| Adela Jiroudkova | Contact | +420 602 145 168 | adela.jiroudkova@ruk.cuni.cz |
| Name | Affiliation | Role |
|---|---|---|
| Kateřina Jiroutková, MD | 3rd Faculty of Medicine, Charles University and FNKV, Prague | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| 3rd Faculty of Medicine and FNKV | Recruiting | Prague | 11000 | Czechia |
Not provided
| ID | Term |
|---|---|
| D053717 | Pneumonia, Ventilator-Associated |
| D011014 | Pneumonia |
| ID | Term |
|---|---|
| D000077299 | Healthcare-Associated Pneumonia |
| D003428 | Cross Infection |
| D007239 | Infections |
| D012141 | Respiratory Tract Infections |
Not provided
Not provided
Eligible patients will be recruited in medical-surgical ICU at Kralovske Vinohrady University Hospital (FNKV), managed under an intensivist-led closed ICU, with a 1:1 nurse-to-patient ratio and randomised in equal proportions between 3% hydrogen peroxide arm and 0,2% chlorhexidine digluconate arm.
Not provided
Not provided
Due to the nature of the intervention nurses can't be blinded to allocation (the mouthwash type - nature of the fluid, its odour etc.), but are strongly inculcated not to disclose the allocation status of the participant at the follow up assessments. As the ICU is paperless and fully computerised, the data in the computer can be acquired and analysed by the researchers without having access to information about the allocation.
|
|
| Chlorhexidine mouthwash | Drug | All patients in experimental arm will receive usual best medical and nursing care with respect to VAP prevention including recently reviewed local "ventilator bundle "; standard microbial surveillance (tracheal aspirate) will be performed twice a week (Monday, Thursday) and always ad hoc according to the clinical situation. This reflects current practice. Daily oral care will be provided using 0,2% chlorhexidine |
|
|
| 18 months |
| ATB exposure at discharge | Duration of antibiotics prescribed at discharge | From the date of enrolment through to the date of ICU discharge, approximately 28 days |
| Intraoral complications, reported using the Bedside oral exam (BOE) score, validated and adopted for ICU. | BOE score ranges from 8 (excellent oral health) to 24 (poor oral health). The BOE scores ranging from 8-10 are considered as indicative of excellent oral health, from 11-14 as moderately impaired oral health and from 15-24 as significantly impaired oral health | will be measured at 24 hours (T1), day 3 (T2), day 7 (T3) and day 14 (T4) after admission |
| Length of ICU stay in days | that is, length of ICU stay in days | at 3 months |
| Number of ventilator-free days; | that is, number of days, out of 28 days after admission, that patient has not been supported by mechanical ventilation | at 28 days |
| day 0, day 7 and day 14 |
| Antibiotic Free Days | The number of days where participant did not require the use of antibiotics | up to 30 days |
| The number of participants with Non-pulmonary infections | The number of participants with Non-pulmonary infections | up to 30 days |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D007049 | Iatrogenic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |